(Q36081653)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

title

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Luigi Mariani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Maria Di Bartolomeo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Angelo Di Leo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Alberto Laffranchi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

author name string

N Zilembo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

C Noberasco

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

E Bajetta

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

S Orefice

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

R Buzzoni

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

language of work or name

English

0 references

publication date

1 October 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

20 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

page(s)

1007-1012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer

20 October 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034036

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034036

4-hydroxyandrostenedione--further clinical and extended endocrine observations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034036

Exemestane (FCE 24304), a new steroidal aromatase inhibitor

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034036

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034036

A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034036

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034036

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034036

Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034036

Formestane as treatment of advanced breast cancer in elderly women

23 September 2018

1 reference

12 December 2020

Urinary 17-hydroxycorticosteroids measured by gas-liquid chromatography

1 reference

12 December 2020

6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor

1 reference

12 December 2020

1 reference

12 December 2020

Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone

1 reference

12 December 2020

Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione

1 reference

12 December 2020

Novel irreversible aromatase inhibitors

1 reference

12 December 2020

The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer

1 reference

12 December 2020

4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Second generation aromatase inhibitor--4-hydroxyandrostenedione

1 reference

12 December 2020

Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1995.451

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7547212%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

PubMed publication ID

7547212

1 reference